Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA) is a synthetic chemical chelating agent, widely used in medical imaging and nuclear medicine, particularly for positron emission tomography (PET) radiopharmaceuticals. It consists of a triazacyclononane (nine-membered ring with three nitrogen atoms) core functionalized with three acetic acid side chains, enabling stable and selective complexation of metal ions, such as gallium-68 (^68Ga^), indium-111 (^111In^), and copper-64 (^64Cu^). Its role is to securely bind radiometals to biomolecules for in vivo targeting, but NOTA itself is not a biological target like a receptor, enzyme, or transporter; rather, it is a chemical tool used for radiolabeling purposes in diagnostic agents. Thus, while essential in radiopharmaceutical chemistry and biomedical imaging, it is not a therapeutic target and does not directly participate in biological pathways or disease mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA).